Core Viewpoint - The company has successfully obtained the Drug Registration Certificate for its trivalent influenza virus split vaccine, marking a significant achievement in its commitment to dual-driven technology and market strategies [1] Group 1: Product Development - The trivalent influenza vaccine was developed by the company's wholly-owned subsidiary, Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd [1] - This vaccine adds to the company's existing portfolio, which includes a quadrivalent influenza vaccine already approved for market and other vaccines in various stages of clinical trials and approval [1] Group 2: Market Strategy - The successful registration of the trivalent influenza vaccine demonstrates the company's innovative research and development capabilities [1] - The company aims to enhance its comprehensive competitiveness and promote sustainable and steady growth by offering a diverse range of high-quality products to meet public health needs [1]